Suppr超能文献

[环孢素A在IgA肾病患者中的长期应用]

[Long-term administration of cyclosporine A in patients with IgA nephropathy].

作者信息

Chábová V, Tesar V, Zabka J, Rychlík I, Merta M, Jirsa M, Stejskalová A, Stejskal J

机构信息

I. interní klinika 1. LF UK a VFN, Praha.

出版信息

Cas Lek Cesk. 1996 Dec 18;135(24):803-6.

PMID:9072300
Abstract

BACKGROUND

IgA nephropathy is the most common glomerulonephritis all over the world and a considerable proportion of the patients reaches end-stage renal failure. Yet the standard treatment for the patients with progressive course and/or great proteinuria is currently lacking. All suggested treatment protocols, including short-term treatment with cyclosporine A had equivocal results. Therefore we decided to try long-term cyclosporine treatment.

METHODS AND RESULTS

We treated 6 patients (4 males, 2 females, age 21-31 years) with bioptically proven IgA nephropathy and proteinuria over 3.5 g/24 hrs with or without nephrotic syndrome non responding to corticosteroid therapy administered for at least 3 months. Patients with serum creatinine greater than 200 mumol/l and/or glomerulosclerosis in more than 50% of glomeruli in renal biopsy were excluded. Pts were given cyclosporine A in initial dose 5 mg/kg bw/day then titrated aiming to the serum concentration of 70-150 ng/ml. Prednisone 5-10 mg on alternate days was given with cyclosporine. Proteinuria decreased during first month of therapy from 4.66 +/- 0.43 g/day to 1.38 +/- 0.29 g/day (p < 0.01) and remained low after one year of treatment (0.59 +/- 0.14 g/day, p < 0.001). Glomerular filtration rate (creatinine clearance) did not change during first month of therapy (1.25 +/- 0.21 ml/s vs. 1.38 +/- 0.29 ml/s), but slightly decreased after one year of treatment (1.05 +/- 0.14 ml/s, p < 0.05). We also calculated ratio of proteinuria to glomerular filtration rate (g/l) to assess the role of hemodynamic changes in the decrease of proteinuria. This ratio was 53.80.10(-3) +/- 15.20.10(-3) before cyclosporin therapy, it decreased significantly after one month (11.56.10(-3) +/- 3.24.10(-3), p < 0.05) and achieved the lowest value after one year of therapy (6.78.10(-3) +/- 4.25 .10(-3) +/- 4.25.10(-3), p < 0.01). Serum cholesterol also significantly decreased after 12 months of therapy (6.21 +/- 0.62 vs. 5.41 +/- 0.45 mmol/l, p < 0.05).

CONCLUSIONS

CyA significantly lowered moderate to high proteinuria with much less decrease of glomerular filtration rate in 6 patients with IgA. Significant decrease of proteinuria/GFR ratio strongly suggests some non-hemodynamic mechanisms of cyclosporine action in these patients. Therapy was well tolerated and side-effects were not so severe to require cyclosporine withdrawal.

摘要

背景

IgA肾病是全球最常见的肾小球肾炎,相当一部分患者会发展至终末期肾衰竭。然而,目前对于病情进展和/或蛋白尿严重的患者仍缺乏标准治疗方案。所有建议的治疗方案,包括短期使用环孢素A治疗,效果都不明确。因此,我们决定尝试长期使用环孢素治疗。

方法与结果

我们对6例经活检证实为IgA肾病且蛋白尿超过3.5g/24小时、伴有或不伴有肾病综合征且对至少3个月的皮质类固醇治疗无反应的患者(4例男性,2例女性,年龄21 - 31岁)进行了治疗。排除血清肌酐大于200μmol/l和/或肾活检中超过50%肾小球出现肾小球硬化的患者。患者初始剂量给予环孢素A 5mg/kg体重/天,然后根据血清浓度调整剂量,目标浓度为70 - 150ng/ml。环孢素治疗期间隔天给予泼尼松5 - 10mg。治疗第一个月蛋白尿从4.66±0.43g/天降至1.38±0.29g/天(p<0.01),治疗一年后仍维持在较低水平(0.59±0.14g/天,p<0.001)。治疗第一个月肾小球滤过率(肌酐清除率)未发生变化(1.25±0.21ml/s对1.38±0.29ml/s),但治疗一年后略有下降(1.05±0.14ml/s,p<0.05)。我们还计算了蛋白尿与肾小球滤过率的比值(g/l),以评估血流动力学变化在蛋白尿减少中的作用。环孢素治疗前该比值为53.8×10⁻³±15.2×10⁻³,治疗一个月后显著下降(11.56×10⁻³±3.24×10⁻³,p<0.05),治疗一年后达到最低值(6.78×10⁻³±4.25×10⁻³,p<0.01)。治疗12个月后血清胆固醇也显著下降(6.21±0.62对5.41±0.45mmol/l,p<0.05)。

结论

环孢素A显著降低了6例IgA患者的中度至高度蛋白尿,同时肾小球滤过率下降幅度较小。蛋白尿/肾小球滤过率比值的显著下降强烈提示环孢素在这些患者中的作用存在一些非血流动力学机制。治疗耐受性良好,副作用不严重,无需停用环孢素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验